CAPTRUST Financial Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

CAPTRUST Financial Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-12,545	Closed	-$1.28M	–	2753
2023 Q2	$1.28M	Buy	+12,545	New	+$1.19M	0.01%	1055
2022 Q3	–	Sell	-27	Closed	-$1K	–	4396
2022 Q2	$1K	Sell	27 -206	-88%	-$6.15K	﹤0.01%	4811
2022 Q1	$8K	Buy	233 +207	+796%	+$6.14K	﹤0.01%	3929
2021 Q4	$1K	Sell	26 -104	-80%	-$8.05K	﹤0.01%	4673
2021 Q3	$13K	Sell	130 -30	-19%	-$3.52K	﹤0.01%	3467
2021 Q2	$23K	Buy	160 +127	+385%	+$14.3K	﹤0.01%	3018
2021 Q1	$3K	Buy	+33	New	+$3.85K	﹤0.01%	3961

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

CAPTRUST Financial Advisors's RETA Position: Q3 2023 in Review

CAPTRUST Financial Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 12,545 shares — an estimated $1.28M sold.

CAPTRUST Financial Advisors first reported a position in RETA in Q1 2021 and held it in 7 quarters. The position peaked at $1.28M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

CAPTRUST Financial Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
CAPTRUST Financial Advisors sold 12,545 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $1.28M.
CAPTRUST Financial Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2021 and held it in 7 quarters.
CAPTRUST Financial Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.28M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2023, filed 15 Nov 2023.